BioNTech resolved ongoing patent litigation with CureVac and GSK by agreeing to pay $740 million plus royalties. The settlement clears regulatory hurdles and facilitates BioNTech’s $1.25 billion acquisition of CureVac, bringing together two mRNA vaccine pioneers. The pact marks a significant consolidation in the mRNA technology landscape, enabling streamlined intellectual property management ahead of the expanded commercialization of mRNA therapeutics and vaccines.